Video

Rapid Readouts: Initial Results of the Phase III BOSTON Study

Author(s):

Cristina Gasparetto, MD, Duke Cancer Institute

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
View More
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
View More
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Related Content
R/R Hematologic Malignancies | Image credit: © Om.Nom.Nom - stock.adobe.com
June 18th 2025

FDA Grants Orphan Drug Designation to SENTI-202 for R/R AML and Hematologic Malignancies

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
October 10th 2022

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

CAR T-cell therapy in DLBCL | Image Credit:© Nicat - stock.adobe.com
June 17th 2025

Axi-Cel, Liso-Cel, and Tisa-Cel Show Comparable Real-World Survival Outcomes in DLBCL

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL
July 28th 2022

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

Amrita Krishnan, MD
June 16th 2025

ASCO 2025 Showcases Emerging Data on MRD-Guided Therapy, Trispecific Antibodies, and Frontline Bispecifics in Myeloma

Anito-Cel in Myeloma | Image Credit: © Curie - stock.adobe.com
June 14th 2025

Anito-Cel Drives Durable Responses in R/R Multiple Myeloma